Cargando…

EGFR Signaling in Lung Fibrosis

In this review article, we will first provide a brief overview of the ErbB receptor–ligand system and its importance in developmental and physiological processes. We will then review the literature regarding the role of ErbB receptors and their ligands in the maladaptive remodeling of lung tissue, w...

Descripción completa

Detalles Bibliográficos
Autores principales: Schramm, Fabian, Schaefer, Liliana, Wygrecka, Malgorzata
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8947373/
https://www.ncbi.nlm.nih.gov/pubmed/35326439
http://dx.doi.org/10.3390/cells11060986
_version_ 1784674423867965440
author Schramm, Fabian
Schaefer, Liliana
Wygrecka, Malgorzata
author_facet Schramm, Fabian
Schaefer, Liliana
Wygrecka, Malgorzata
author_sort Schramm, Fabian
collection PubMed
description In this review article, we will first provide a brief overview of the ErbB receptor–ligand system and its importance in developmental and physiological processes. We will then review the literature regarding the role of ErbB receptors and their ligands in the maladaptive remodeling of lung tissue, with special emphasis on idiopathic pulmonary fibrosis (IPF). Here we will focus on the pathways and cellular processes contributing to epithelial–mesenchymal miscommunication seen in this pathology. We will also provide an overview of the in vivo studies addressing the efficacy of different ErbB signaling inhibitors in experimental models of lung injury and highlight how such studies may contribute to our understanding of ErbB biology in the lung. Finally, we will discuss what we learned from clinical applications of the ErbB1 signaling inhibitors in cancer in order to advance clinical trials in IPF.
format Online
Article
Text
id pubmed-8947373
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-89473732022-03-25 EGFR Signaling in Lung Fibrosis Schramm, Fabian Schaefer, Liliana Wygrecka, Malgorzata Cells Review In this review article, we will first provide a brief overview of the ErbB receptor–ligand system and its importance in developmental and physiological processes. We will then review the literature regarding the role of ErbB receptors and their ligands in the maladaptive remodeling of lung tissue, with special emphasis on idiopathic pulmonary fibrosis (IPF). Here we will focus on the pathways and cellular processes contributing to epithelial–mesenchymal miscommunication seen in this pathology. We will also provide an overview of the in vivo studies addressing the efficacy of different ErbB signaling inhibitors in experimental models of lung injury and highlight how such studies may contribute to our understanding of ErbB biology in the lung. Finally, we will discuss what we learned from clinical applications of the ErbB1 signaling inhibitors in cancer in order to advance clinical trials in IPF. MDPI 2022-03-14 /pmc/articles/PMC8947373/ /pubmed/35326439 http://dx.doi.org/10.3390/cells11060986 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Schramm, Fabian
Schaefer, Liliana
Wygrecka, Malgorzata
EGFR Signaling in Lung Fibrosis
title EGFR Signaling in Lung Fibrosis
title_full EGFR Signaling in Lung Fibrosis
title_fullStr EGFR Signaling in Lung Fibrosis
title_full_unstemmed EGFR Signaling in Lung Fibrosis
title_short EGFR Signaling in Lung Fibrosis
title_sort egfr signaling in lung fibrosis
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8947373/
https://www.ncbi.nlm.nih.gov/pubmed/35326439
http://dx.doi.org/10.3390/cells11060986
work_keys_str_mv AT schrammfabian egfrsignalinginlungfibrosis
AT schaeferliliana egfrsignalinginlungfibrosis
AT wygreckamalgorzata egfrsignalinginlungfibrosis